Last reviewed · How we verify
Remifentanil-high dose
At a glance
| Generic name | Remifentanil-high dose |
|---|---|
| Also known as | Ultiva |
| Sponsor | Yonsei University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Trial of Tegileridine Fumarate Lnjection for Prolonged Mechanical Ventilation Abirritation in the Intensive Care Unit (ICU) (PHASE2)
- Effect of Liposome Bupivacaine Serratus Plane Block on Postoperative Hyperalgesia and Chronic Post-surgical Pain in Patients Undergoing Radical Mastectomy (PHASE1, PHASE2)
- Near Infrared Spectroscopy Cortical Response to Noxious and Auditory Stimuli in Subjects Under General Anesthesia (NA)
- Remifentanil Effect on Burst Suppression Ratio (NA)
- Minimal Flow Anesthesia and Infection Risk (NA)
- PECS-II vs ESP in Nociception Level Index Guided Breast Surgery (NA)
- Effect of Ultra-low Dose Naloxone on Remifentanil-Induced Hyperalgesia (PHASE2)
- Venous Cannulation Pain to Guide Choice of Anesthetic Method (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Remifentanil-high dose CI brief — competitive landscape report
- Remifentanil-high dose updates RSS · CI watch RSS
- Yonsei University portfolio CI